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Introduction  
 INTRODUCTION  
 The term diabetes mellitus describes several diseases of abnormal 
carbohydrate metabolism that are characterized by hyperglycemia. It is 
associated with a relative or a absolute impairment in insulin secretion, along 
with varying degrees of peripheral resistance to the action of insulin.  
 The American Diabetes Association recommends the fasting plasma 
glucose because it is easier, faster and less expensive to perform. With the 
FPG test, a fasting glucose level between 100 and 126 mg/dl signals pre-
diabetes. A person with a fasting blood glucose level of 126 mg/dl or higher 
has diabetes. One can also use oral glucose tolerance test (OGTT) to diagnose 
diabetes, but OGTT is cumbersome and hence is not preferred at most centers. 
It is  performed  by measuring  a blood glucose level in the fasting state and 
again two hours after taking 75g of glucose or any glucose rich beverage. If 
the two hour blood glucose value is at 200 mg/dl or higher, the person tested 
has diabetes.  
 The estimated prevalence of diabetes worldwide is about 3,822,720 for 
the year 2003. This amounts to 5% of the world population. The South East 
Asian Region accounts for 705,292 cases. The estimated population affected 
in India is 6,03,677. With such high prevalence it is essential to institute 
measures to prevent diabetes hence the ADA has introduced the term 
prediabetes for IFG and IGT to create awareness.  
  The diabetes control and complications trial showed that intensive 
control of the blood sugar over a 7 year study interval reduced the progression 
of diabetic retinopathy, nephropathy and neuropathy1.  
 The relationship between control and complications in type 2 diabetes 
was evaluated in the united kingdom prospective diabetes study2. The study 
concluded that for every 1% decrease in glycosylated hemoglobin A1c there 
was a 35% reduction in the risk of microvascular complications. Diabetes 
complicates almost every organ and is the fourth major cause of mortality and 
morbidity world wide.  
 With the agreeable exception of pain, the autonomic manifestations of 
diabetes are responsible for the most troublesome and disabling feature of 
diabetic neuropathy and results in a significant proportion of the mortality and 
morbidity associated with the disease.  A broad constellation of symptoms 
occur that affect cardiovascular, urogenital, gastro intestinal, pupillomotor, 
regulatory and sudomotor functions. The impairment is usually gradual and 
progressive, although severe autonomic dysfunction occurs shortly after the 
diagnosis of type 2 diabetes in rare cases3. The availability of sensitive, 
specific and  reproducible  non invasive tests of autonomic function has 
enhanced our  understanding of the prevalence, pathophysiology and clinical 
manifestations of this disorder4. Estimates of the prevalence of diabetic 
autonomic neuropathy are dependent on the criteria used for diagnosis and the 
specific population under study.  
  The cardiovascular autonomic neuropathy has diverse manifestations. 
An increased resting heart rate is observed frequently in diabetic patients; 
most likely this is due to the vagal  cardiac neuropathy that results in 
unopposed cardiac sympathetic nerve activity.  
 The tachycardia may be followed by a decrease in heart rate and 
ultimately a fixed heart rate due to the progressive dysfunction   of the cardiac 
sympathetic nervous system5.  
 Orthostatic hypotension, the most incapacitating manifestation of 
autonomic failure, is a common feature of diabetic cardiovascular autonomic 
neuropathy. This is a consequence of efferent sympathetic vasomotor 
denervation than causes reduced vasoconstriction of the splanchic and other 
peripheral vascular beds. Diminished cardiac acceleration and cardiac output, 
particularly in association with exercise, also may play a role in the 
presentation of this disorder.  
 Several authors have drawn attention to the association between 
increased mortality and cardiovascular autonomic dysfunction in patients with 
diabetes. Estimates of the mortality associated with cardiovascular autonomic 
neuropathy   range from 27% to 56% over a period of 5-10 years after its 
onset. There is also an increased frequency of sudden death in patients with 
cardiac autonomic neuropathy.  
 Proposed mechanisms by which the autonomic nervous system may 
result in sudden death or influence the outcome of patients with diabetes who 
have cardiovascular disease include absent or altered perception of  
 myocardial ischemia and infarction, deficient hemodynamic response to 
cardiovascular stresses such as surgery, infection and anesthesia; increased 
predisposition  to cardiac arrhythmias  due to QT interval dispersion; and  
alterations in sympathetic – parasympathetic cardiac innervation balance 6,7. 
 It is in this background that we endeavour to analyse the prevalence of 
cardiac autonomic neuropathy in type 2 diabetic patients using clinical 
methods and cardiovascular autonomic function tests. This study also aims to 
find the electrocardiographic changes associated with diabetes mellitus.  
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AIM OF THE STUDY 
 
1. To study the prevalence of cardiac dysautonomia in  
type 2 diabetic patients by clinical and electrocardiographic 
methods.  
2. To study the prevalence of various ECG abnormalities in type 2 
diabetic patients as compared to controls. 
3. To study the correlation between symptoms and signs of cardiac 
dysautonomia in type 2 diabetic patients. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 REVIEW OF LITERATURE  
 Diabetes mellitus comprises a group of common metabolic disorders 
that share the phenotype of hyperglycemia. The metabolic dysregulation 
associated with DM causes secondary pathophysiologic changes in multiple 
organ systems that impose a tremendous burden on the individual with 
diabetes and on the health care system. 
 The worldwide prevalence of DM has risen dramatically over the past 
2 decades. Likewise, prevalence rate of impaired fasting glucose are also 
increasing. Although the prevalence of both type 1 and type 2 DM is 
increasing worldwide, the prevalence type 2 DM is expected to rise more 
rapidly in the future because of increasing obesity and reduced activity levels.  
WHO FACT SHEET 
Prevalence of Diabetes World Wide  
Region 
Prevalence      (Year 
2000) 
Projected estimate 
(Year 2030) 
World 171,000,000 366,000,000 
South East Asia 49,903,000 119,541,000 
India 31,705,000 79,441,000 
 In 2000, the prevalence of DM was estimated to be 0.19% in people 
<20 years old and 8.6% in people >20 years old. In individuals >65 years of 
 age the prevalence of DM was 20%. The prevalence is similar in men and 
women throughout most age groups but is slightly greater in men after 60 
years of age.  
 There is considerable geographic variation in the incidence of both 
type 1 and type 2 DM. The prevalence of type 2 DM and its harbinger, IGT is 
highest in certain Pacific Islands, intermediate in countries such as India and 
the United States and relatively low in Russia and China. This variability is 
likely due to genetic, behavioural and environmental factors.  
 The results of prevalence studies of DM in India were systematically 
reviewed with emphasis on those utilizing the standard WHO criteria for 
diabetes diagnosis. The prevalence of diabetes in adults was found to be 2.4% 
in rural and 4.0 – 11.6% in urban dwellers 8. 
 High frequencies of impaired glucose tolerance, shown by these 
studies, ranging from 3.6 – 9.1%, indicate the potential for further rise in 
prevalence of diabetes mellitus in the coming decades8. 
  
Recently the WHO in consultation with an expert  committee of the 
American Diabetes Association  has approved a new diagnostic criteria for 
DM. 
Diagnostic criteria 
 Category FPG PPG 
Normal  <100mg/dl                  ( 
5.6 mmol/L) 
<140mg/dl                  
(<7.8 mmol/L) 
IFG 100 – 125 mg /dl            
(5.6 – 6.9 mmol/L) 
- 
IGT - 140 – 199 mg/dl 
(7.8 – 11.0 mmol/L) 
Diabtes  ≥ 126 mg /dl               (≥ 
7.0 mmol/L) 
≥ 200 mg /dl               
(≥11.1 mmol/L) 
Fasting: No caloric intake for atleast 8 hours.  
  
When the diagnosis of diabetes is made it is confirmed by a repeat 
testing done on a different day. 
                                       
 DIABETES AND THE HEART 
 Diabetes is a major risk factor for cardiovascular mortality. It affects 
the heart in these ways.  
• Coronary artery disease  
• Small vessel disease 
• Diabetic cardiomyopathy 
• Heart failure  
• Cardiac autonomic neuropathy 
Coronary Artery Disease  
Coronary artery disease is about twice as frequent in diabetic men and 
four times as frequent in diabetic women after menopause compared to the 
respective non diabetics. In fact one third of all deaths occurring in diabetics 
after 40 years of age have been attributed to coronary artery disease. CAD in 
diabetes is characterized by greater prevalence of triple vessel disease. 
Clinically CAD in diabetic subjects is associated with prematurity and 
asymptomatic heart disease. An abnormal resting ECG has been documented 
in about 40% of normotensive, ambulant diabetic subjects. On exercising, the 
prevalence of ECG abnormalities among diabetic subjects is twice compared 
to non - diabetics. Silent myocardial infarction is an entitity with a greater 
prevalence in diabetic subjects.  
Small Vessel Disease  
  In addition to the classical atherosclerosis affecting the large 
extramural vessels, occlusive disease process affecting the smaller vessels is 
the hallmark of diabetic heart disease. Pathological changes are seen in the 
endothelium, elastic and intima in the small arteries. The resultant ischemia 
produces widespread fibrosis in the ventricular interstitium with impaired left 
ventricular function. Syncope, conduction disturbances, arrhythmias and even 
sudden death may be produced by small vessel disease of sinoatrial node or 
atrioventricular node. 
Diabetic Cardiomyopathy  
 This refers to the derangement in the myocardium in the absence of 
extramural coronary atherosclerosis. Increased accumulation of connective 
tissue in the myocardium surrounding the smaller intramural vessels has been 
histologically documented. The localized saccular aneurysms of arterioles 
may involve any layer of ventricular myocardium. Morphological analysis of 
the diabetic myocardium reveals accumulation of glycoprotein material with a 
less compliant ventricular wall.  Non invasive and invasive techniques have 
enabled the identification as well as quantification of the degree of ventricular 
impairment. ST and T wave changes in ECG are very early changes in 
diabetic cardiomyopathy. The thickness of the ventricular septum has been 
correlated with the insulin concentration. The systolic time interval is a very 
sensitive index of left ventricular dysfunction. The ratio of pre-ejection 
period: left ventricular ejection time is increased in diabetic subjects and is 
 attributed to asynchronous and incoordinate myocardial contraction, and has 
been found to correlate with the ambient blood glucose levels. The delay in 
mitral valve opening relative to minimum cavity dimensions accounts for the 
prolonged relaxation of the diabetic myocardium. 
Heart Failure 
 There is a high frequency of diastolic dysfunction accompanied by an 
increased mortality risk for patients with diabetes. The poor prognosis for 
these patients has been explained by an underlying diabetic cardiomyopathy 
exacerbated by hypertension and ischemic heart disease. Epidemiological data 
shows that heart failure is two times as common in diabetic men and five 
times as common in diabetic women as in age – matched non diabetic 
subjects .Evidence from large clinical trials has shown that remodeling can be 
attenuated, ventricular function improved and mortality  and morbidity 
reduced by drugs that interfere with the enhancement of the neurohormonal 
systems.  
AUTONOMIC NERVOUS SYSTEM 
                    The autonomic nervous system innervates the entire neuraxis and 
permeates all organ systems. It regulates blood pressure, heart rate, sleep and 
bladder and bowel function. It operates in the background, so that its full 
importance becomes recognized only when its function is compromised, 
resulting in dysautonomia. 
                  The preganglionic neurons of the parasympathetic nervous system 
leave the central nervous system in the third, seventh, ninth and tenth cranial 
nerves as well as the second, third and fourth sacral nerves, while the 
preganglionic neurons of the sympathetic nervous system exit the spinal cord 
between the first thoracic and second lumbar segments. The post ganglionic 
neurons located in ganglia outside the CNS gives rise to post ganglionic 
autonomic nerves that innervate organs and tissues throughout the body. 
 Functional consequences of normal ANS Activation 
Parameters Sympathetic Parasympathetic 
Heart rate Increased Decreased 
Blood pressure Increased Mildly decreased 
Bladder Increased sphincter tone Voiding 
Bowel motility Decreased motility Increased 
Lung Bronchodilation Bronchoconstriction 
Sweat glands Sweating  _ 
Pupils Dilation Constriction 
Adrenal Glands Catecholamine release _ 
Sexual function  Ejaculation, orgasm Erection 
Lacrimal Glands _ Tearing 
Parotid Glands _ Salivation 
 
Responses to sympathetic and parasympathetic stimulation are 
frequently antagonistic, reflecting highly coordinated interactions within the 
CNS; the resultant changes in parasympathetic and sympathetic activity 
provide more precise control of autonomic responses than could be achieved 
by the modulation of a single system. 
Diabetic Autonomic Neuropathy  
 DAN, a subtype of the peripheral polyneuropathies that accompany 
diabetes, can involve the entire autonomic nervous system. DAN is a serious 
and common complication of diabetes. Despite its relationship to an increased 
risk of cardiovascular mortality and its association with multiple systems and 
impairment, the significance of DAN has not been fully appreciated.  
DAN has been called a silent killer, because so few patients realize that 
they suffer from it and yet its effects can be so lethal. 
DAN may be either clinically evident or subclinical. It is manifested by 
dysfunction of one or more organ systems (cardiovascular, gastrointestinal, 
genitourinary, sudomotor, ocular)9. 
 Sub clinical autonomic dysfunction can occur within a year of 
diagnosis in type 2 diabetics and within 2 years in type 1 diabetics10,11,12. 
Based even on asymptomatic subjects with abnormality only in 
autonomic function tests, the overall mortality rate may be as high as 25% to 
40% over 10 years13.  
 SYMPTOMS AND SIGNS OF DAN 
Cardiovascular System 14   
• Postural hypotension  
• Painless myocardial infarction  
• Resting tachycardia  
• Loss of heart rate variation  
Gastro Intestinal System 
• Impaired esophageal motility  
• Gastroparesis  
• Diarrhea 
• Colonic atony 
• Enlarged gall bladder 
Urogenital System 
• Bladder dysfunction  
• Impotence  
• Retrograde ejaculation 
• Loss of testicular sensation   
Respiratory System 
• Respiratory arrest  
Pupillary Abnormalities  
 • Reduced resting diameter 
• Delayed or absent response to light  
• Diminished hippus  
Vasomotor System 
• Loss of skin vasomotor responses  
• Peripheral vascular changes 
• Osteopathy (Charcot’s arthropathy)  
• Dependent edema  
Sudomotor Features 
• Diabetic anhydrosis  
• Gustatory sweating  
Hypoglycemia Unawareness  
• Decreased catecholamine  release with loss of warning symptoms of 
hypoglycemia  
• Decreased pancreatic glucagons and pancreatic polypeptide release.  
 DIFFERENTIAL DIAGNOSIS OF CAN 
Clinical features Differential Diagnosis  
Tachycardia  
Exercise intolerance  
• Idiopathic Orthostatic  
Hypotension 
• Multiple system atrophy with 
parkinsonism  
• Hyperadrenergic hypotension  
Cardiac denervation  
Painless myocardial infarction  
• Shy Drager Syndrome  
• Panhypopituitarism  
• Pheochromocytoma 
Orthostatic hypotension  • Hypovolemia 
• Congestive Heart Disease  
• Carcinoid syndrome   
ETIOPATHOGENESIS 
 The precise pathogenesis of diabetic neuropathy is still not fully 
understood however clinical observation and studies using animal models of 
experimental diabetes suggest that hyperglycemia and other metabolic 
derangement might directly induce damages to neurons and nerve 
parenchyma15. 
 In parallel reduced neurovascular blood flow might also cause 
ischemic neuronal damages15. 
 Multiple abnormalities in diabetic states, including the activation of 
protein Kinase C, enhanced oxidative stress, formation of advanced 
 glycosylation end products in neuronal tissues and altered expression of 
neurotrophic  factors such as nerve growth factor and IGF -1 have all been 
reported to be important determinants for the pathogenesis of  diabetic  
neuropathy 16,17. 
 Vascular etiology in diabetic neuropathy is supported by multiple 
abnormalities in the microvasculature, including the deposition of AGE in the 
perineuronal vascular wall, basement membrane thickening, endothelial cell 
swelling and loss of pericytes, reduced endothelial nitric oxide activity and 
capillary occlusion16 and degeneration of blood vessels supplying neuronal 
tissues18. All the changes eventually contribute to hyperglycemia induced 
decrease in neurovascular blood flow and the subsequent hypoxia – ischemic 
damage19. 
 Gene transfer of VEGF in experimental diabetic animal models has 
been reported to restore blood flow in neuronal tissues and rectify the 
conductivity of the nerves that were impaired in diabetic states18,20. 
 Vascular (Ischemic – hypoxic) Theory20 
 According to this theory, endoneural ischemia develops  because of 
increased endoneural vascular resistance to hyperglycemic blood. Various 
metabolic factors, including formation of AGE products also have been 
implicated. The end results are capillary damage, inhibition   of axonal 
transport, decreased sodium / potassium ATPase activity, and finally axonal 
degeneration.  
Metabolic Theory  
 This theory proposes that hyperglycemia causes increased levels of 
intracellular glucose in nerve, leading to saturation of the normal glycolytic 
pathway. Extra glucose is shunted through polyol pathway and converted to 
sorbitol and fructose by the enzymes, aldose reductase and sorbitol 
dehydrogenase. Accumulation of sorbitol and fructose lead to decreased nerve 
myoinositol, decreased membrane sodium/ potassium ATPase activity, 
impaired axonal transport and structural breakdown of nerves, causing 
abnormal action potential  propagation.  
Altered Neurotrophic Support Theory  
 Nerve growth factor is the best studied of the neurotrophic factors. 
This protein promotes survival of sympathetic and small fibre neural crest 
derived elements in the PNS. Antioxidants have been used to enhance the 
effects of NGF. 
 Laminin Theory  
 Laminin is a large heteromeric glucoprotein composed of a large α and 
two smaller  β chains, β1 and β2. In altered neurons, laminin promotes neurite 
extension. Lack of normal expression of the laminin β2 gene may contribute 
to the pathogenesis of diabetes neuropathy. 
Autoimmune Theory  
 This favours autoimmune damage to endothelial capillary cells.  
Antibodies to endothelial cells decreases microvascular supply to neurons. 
Inflammatory Theory 
 Diabetic patients have increased plasma level of inflammatory markers 
such as C reactive protein, IL-6, and TNF - α that are associated with 
endothelial dysfunction21. 
 OXIDATIVE STRESS 
Hyperglycemia 
 
The roles of hyperglycemia – induced accumulation of ROS and oxidative stress in 
diabetic vascular complications. In diabetic states, hyperglycemia regulates the multiple steps of 
the production and clearance of ROS and is in favour of ROS accumulation. Such events include 
the production of superoxide from endothelial nitric oxide synthase (eNOS) uncoupling, activation 
of PKC, AGE formation, and increased flux through polyol pathway. In addition to the increased 
activity of NAD(P) H oxidase, mitochondrial production of ROS is also increased and results in 
the overproduction of superoxide O2,  which is the major  from of ROS that causes vascular 
oxidative stress. This is turn, contributes to diabetic vascular complications as illustrated. 
VASCULAR PATHOLOGY 
Hyperglycemia  
  
Vascular pathological changes  
 Role of AGE accumulation in diabetic vascular complications. Hyperglycemia induces the 
glycation of multiple extracellular and intracellular proteins known collectively as AGE. The 
glycation modification of proteins not only alter the function of strcture proteins, but also activate 
intracellular signaling pathways through receptor for AGE (RAGE) that contributes to the 
development of diabetic vascular  complications. 
 
 
INTRA CELLULAR PATHWAYS 
Hyperglycemia  
  
Activation of the hexosamine pathway in response to hyperglycemia and its role in 
diabetic vascular complications. Increased action of the key enzymes in the hexosamine pathway 
including glutamine: fructose – 6 – phosphate aminotrasferease GFAT and O- GlcNAC 
transferase OGTase induces the flux through the hexosamine pathway that can result in the O-
linked glycosylation of may proteins. Increased glycolysis induces the induction of flux through 
the hexosamine pathway. There is also cell culture study suggested the increased transcription of 
GFAT in response to AT- IR activation that requires that transactivation of epidermal growth 
factor receptor (EGFR). The increased hexosamine pathway activity is modification can prevent 
hte serine phsophorylation of multiple key enzymes and transcriptional factors that alter vascular 
hemodynamic and gene expression. These changes have been suggested to play a role in and 
transcriptional factors that alter vascular hemodynamic and gene expression. These changes have 
been suggested to play a role in the develoopment of diabetic  vascular complications. 
TRANSCRIPTION DEFECTS  
Hyperglycemia 
  
Activation of intracellular signaling cascades by hyperglycemia lead to multiple vascular 
pathological changes in diabetes. Hyperglycemia could activate intracellular signaling pathways 
via several mechanisms independently, including actions of cell surface receptors, formation of 
AGE, oxidative stress, and intermediates of the glycolysis pathways. The activation of these 
intracellular signaling molecules, especially the PKC-β and -δ isoforms, have been shown to 
regulate vascular cell growth and apoptosis, gene expression, vascular permeability, hemodynamic 
changes, oxidative stress, and inflammation. Clinical trials are ongoing evaluating selective 
inhibition of PKC-β in the treatment of diabetic retinopathy and neuropathy. 
 
CARDIOVASCULAR AUTONOMIC NEUROPATHY 
 This occurs in about 17% of patients with type 1 DM and 22% of those 
with type 2 DM. An additional 9% of type 1 patients and  12% of type 2 
patients have borderline dysfunction22. 
  Using cardiovascular reflex tests, the prevalence is reported to be 17% 
to 40% 23-27. Of teenagers with type 1 DM 31% have abnormal  results23. 
 The prevalence is associated with both duration of diabetes28and with 
age and is equal to or higher in type 2 than in type 1 DM29. 
 When symptoms of autonomic neuropathy are present, the anticipated 
mortality rate is 15% - 40% with in five years 30,31,32. 
 A metaanalysis of eleven studies concluded that five year  mortality 
was 5% among patients  with normal heart rate variability compared to 27% 
among those with abnormal HRV33. A recent prospective study has shown the 
prevalence of DAN in the EURODIAB IDDM complication study to be 
36%34. 
 There has been a considerable variation in prevalence as is evident in 
these studies. The reported prevalence of DAN varies with community based 
studies finding lower rates than clinic and hospital based studies in which the 
prevalence may be as high as 100%35. 
Pathology 
 In an autopsy study of patients with symptoms of autonomic 
neuropathy, Duchen and colleagues found infiltration of lymphocytes, 
macrophages and plasma cells in and around autonomic nerve bundles and 
ganglia36. 
  Further studies in diabetic rodents  and human sympathetic ganglia at 
autopsy have demonstrated axonal and dendritic pathology  in sympathetic 
ganglia in the absence of significant neuron loss as the neuropatholgoical 
hallmark of DAN37. 
 A recurring theme in sympathetic ganglia as well as in the post 
ganglionic autonomic innervations of various end organs, is the involvement 
of distal portions of axons and nerve terminals by degenerative or dystrophic 
changes. There is a marked enlargement of distal preterminal axons and 
synapses, and this is the most notable alteration in sympathetic ganglia in 
diabetic patients38. 
 MANIFESTATIONS OF CAN 
Resting Tachycardia and Diminished HRV 
 Resting tachycardia is an early sign of autonomic neuropathy. 
Tachycardia increases the risk of atherosclerosis39,40 and distensibility of the 
vascular wall is reduced by tachycardia41. It is important to realize that 
clinical implication of HRV analysis has been clear recognized in only 2 
clinical conditions42. 
a. as a predictor of risk of arrhythmogenic events or SCD after 
acute myocardial ischemia. 
b. As a clinical marker of evolving diabetic neuropathy.  
Left Ventricular Dysfunction  
 There is evidence of left ventricular dysfunction in particular diastolic 
dysfunction in patients with DAN43. Parasympathetic impairment and 
nocturnal elevations in blood pressure could be the link between autonomic 
neuropathy and diastolic ventricular dysfunction44. Diastolic function is 
usually impaired first followed by systolic dysfunction45. 
 Decreased Myocardial Reserve  
DAN patients have a decreased myocardial perfusion reserve capacity 
when challenged with a vasodilator. The underlying mechanism may be 
defective myocardial sympathetic vasodilatation, a lack of ability to maintain 
blood pressure during vasodilatation or both46. The heart rate, blood pressure 
and cardiac output responses to exercise are significantly impaired in diabetic 
neuropathic patients47. 
Silent Myocardial Ischemia  
 During a 4.5 year followup of diabetic patients with autonomic 
neuropathy accompanied by silent myocardial ischemia, a serious 
cardiovascular event was recorded in 50%48. 
Increased Risk Of Coronary Artery Disease  
 Recent studies have shown an association between autonomic 
neuropathy and increased coronary heart disease risk49. 
 Autoimmune neuropathy 5 years after diagnosis of type 2 diabetes is 
associated with an unfavourable metabolic risk profile, and parasympathetic 
neuropathy in type 2 diabetes patients is associated with features of the insulin 
resistance syndrome50. The high platelet activation may reflect an increased 
pro-thrombotic state in diabetic cardiovascular autonomic dysfunction51.  
 Further more, cardiovascular autonomic neuropathy is related to 
increased plasminogen activator inhibitor52. Increased arterial stiffness may be 
of importance in the increased susceptibility to cardiovascular complications 
in diabetic women53. Sympathetic denervation of arteries leads to medial 
smooth muscle degeneration and calcification54. 
Loss  Of Circadian Rhythm Of Blood Pressure  
 Nocturnal blood pressure in patients with diabetic autonomic 
neuropathy is higher than that in non diabetic subjects. Monitoring blood 
pressure over 24 hours confirms this flattening in nocturnal blood pressure 
reduction at night and shows increased blood pressure values55. This may 
cause cardiac hypertrophy and is postulated as one possible cause of increased 
mortality56. 
Postural Hypotension  
 Maintenance of blood pressure on standing depends on afferent 
impulses from baroreceptors and efferent sympathetic impulses to the heart 
and blood vessels. Postural hypotension; that is a fall in systolic pressure of 
more than 30 mm Hg, on standing, occurs in diabetic subjects with advanced 
neuropathy, although symptoms are infrequent. 
 Blood flow studies show that the reduction in foot blood flow on 
standing observed in normal subjects is diminished in diabetic patients with 
postural hypotension, although significant vasoconstriction still occurs57. 
  Another important mechanism is the failure of the splanchnic bed to 
vasoconstrict on standing.  Failure of cardiac acceleration and reduced cardiac 
output both contribute to the problems. Nor adrenaline levels are generally 
reduced in diabetic patients with postural hypotension.  
 Insulin is known to have cardiovascular effects58. It causes a reduction 
in plasma volume, an increase of peripheral blood flow from vasodilatation 
and an increase in heart rate. In patients with autonomic neuropathy, insulin 
may cause an exacerbate postural hypotension to the point of fainting, 
whether it is given intravenously or subcutaneously and occasionally a 
blackout may occur from hypotension. 
 Both hypotension and its symptoms fluctuate spontaneously to a 
remarkable degree and may persist for many years without necessarily 
deteriorating59. 
Postprandial Hypotension  
 In diabetic patients with autonomic neuropathy observations 
established that while food causes a large increase in mesentric  blood flow, 
the latter does not coincide with an exacerbation of their hypotension60.  
CARDIOVASCULAR AUTONOMIC FUNCTION TESTS 
Tests for Parasympathetic Function  
• Heart rate response to deep breathing  
 • Heart rate response to standing  
• Heart rate response to valsalva manuover.  
Tests for Sympathetic Function  
• Blood pressure response to standing  
• Blood pressure response to sustained hand grip 
 
 
Sl.No Cardiac autonomic  function tests Normal Abnormal 
1 Heart rate variation during deep 
breathing  (E:I ratio) 
>1.1 ≤1.1 
2 Heart rate increase on standing 30: 
15 ratio  
>1.04 <1.00 
3 Valsalva ratio  >1.2 <1.2 
4 
 Blood pressure response  on 
standing  (Systolic pressure  fall at 
2 min [mm Hg]) 
<10 >30 
5 Blood pressure to sustained hand 
grip (rise in diastolic blood 
pressure [mmHg]) 
>16 <10 
NONINVASIVE  CARDIOVASCULAR REFLEX TESTS 
Heart Rate Response to Deep Breathing  
  The normal acceleration and deceleration of heart rate during 
respiration (sinus arrhythmia) is decreased early in course due to cardiovagal 
involvement. This phenomenon provides the basis for the simplest and most 
sensitive test for the presence of cardiac dysautonomia. The patient takes 
breath deeply and evenly at a rate of 6 breaths per minutes (i.e.,) 5 seconds for 
inspiration and 5 seconds for expiration. The maximum and minimum heart 
rate during this breathing cycle is calculated from the ECG recording. The 
difference between 3 successive breathing cycles gives  
max – min heart rate variation as E: I ratio. 
Heart Rate Response To Standing  
 When the patient is made to stand from a lying posture there is a 
characteristic rapid increase in heart rate. This is maximum at 15th heart beat 
after standing followed by a relative overshoot bradycardia which is 
maximum at 30th beat. This is represented as a ratio (30th Beat) R-R  : (15th 
Beat) R-R  minute ratio in the ECG recording.  
Heart Rate Response To Valsalva  Manoeuvre 
 Blood pressure falls and heart rate increases during strain phase of 
valsalva manoeuvre and after release the blood pressure rises with the slowing 
of heart rate. In patients with cardiac dysautonomia there is a fall is blood 
pressure during the strain phase and after release, slowly the blood pressure 
returns to normal with no variation  in heart rate. This test can be performed 
 using an aneroid manometer. The valsalva ratio is the ratio of longest R-R / 
shortest R-R intervals; the normal value being more than 1.1. 
 Blood Pressure Response to Standing  
 Blood pressure recording is done when the subject is lying down and 
again two minutes after standing up. The difference in systolic blood pressure 
from lying to standing posture is taken as a measure of postural hypotension. 
The response is abnormal if the blood pressure decreases by more than 30 
mmHg within two minutes of standing.  
Blood pressure response to Sustained Exercise 
A hand grip dynamometer is squeezed to 30% of maximum 
(predetermined in the subject) for 5 minutes. The normal response is an 
increase of diastolic blood pressure of approximately 16 mm Hg. A rise of 
less than 10mmHg is considered abnormal.  
 These tests form the core of diagnosis of cardiac autonomic 
neuropathy. They are validated, reliable and reproducible. They correlate with 
each other and with tests of peripheral somatic nerve functions. 
 A recent study has provided age specific and sex specific reference 
values for a wide range of different autonomic function measures in elderly 
population61. 
 Spectral Analysis of Heart Rate Variability  
 The development of power spectrum analysis has facilitated the 
diagnosis of autonomic neuropathy. HRV can be assessed in the time domain 
(by statistical analysis of RR intervals) and in the frequency domain (by 
spectral analysis of a series of successive RR intervals). Electrocardiogram 
recording is made for at least five minutes to allow spectral analysis to be 
carried out. 
 In the time domain, the simplest parameter is the standard deviation of 
RR intervals. Three frequency domains are usually measured.  
• A high frequency  (HF) component that is a reflection of 
respiratory sinus arrhythmia  and is an index of vagal activity;  
• A low frequency (LF) component reflecting vasomotor activity 
and is dependent on both sympathetic and vagal tone;  
• Among low frequency (VLF) band representing  
the influence of the peripheral vasomotor and  
renin – angiotensin system62. 
DAN is associated with a reduction of HRV. Both the LF and HF 
components diminish before onset of clinical neuropathy. This suggests 
similar damage to both sympathetic and parasympathetic pathways of the 
heart. 
Measurement of baroreflex sensitivity 
  The arterial baroreflex maintains the stability of blood pressure. 
Changes in BP lead to stimulation of the baroreceptors, which activates 
cardiac vagal fibers and sympathetic outflow to the heart and the peripheral 
blood vessels. Vagal tone is maintained by reflex mechanisms that activate 
the baroreceptors. Thus baroreflex sensitivity can be measured from the reflex 
heart rate response to changes in BP.A change in BP can be induced 
pharmacologically, or the spontaneous fluctuations of BP in steady state 
conditions may be used. 
Thus short noninvasive recording of the BP and RR interval signals are 
taken in the supine position. The baroreflex sensitivity is determined by the 
regression analysis of changes induced in the length of RR interval by 
spontaneous fluctuations in BP. Baroreflex sensitivity is impaired in diabetics 
and is helpful in the early detection of cardiac autonomic neuropathy. 
 MANAGEMENT 
MANAGEMENT OF PATHOGENETIC MECHANISMS 
Strict glycemic control 
When we detect DAN the first and foremost important focus of 
treatment is blood sugar control. Until recently, researchers were unaware as 
to whether high blood sugar levels were actually responsible for the 
complications of diabetes. In 1993, the results of DCCT largely put those 
doubts to rest. The most important thing that we can do for patients with 
diabetes are to make them aware of autonomic neuropathy, to let them know 
whether they have it and keep blood sugar levels within acceptable range. 
Aldose reductase inhibitors 
• Alrestatin 
• Sorbinil 
• Tolrestat 
• Zenerestat 
Aldose reductase inhibitors reduce the flux of glucose through the 
polyol pathway,inhibiting tissue accumulation of sorbitol and fructose and 
preventing reduction of redox potentials. 
 Myo -inositol 
         There are several studies suggesting that myo-inositol supplements of 
the normal diet improves neuropathy, but the treatment may have to be 
prolonged for atleast six months for significant results to be achieved. 
Trends for the future 
Alpha Lipoic acid  
This is a derivative of octanoic acid and is present in food and is also 
synthesized in liver. It has been shown to be effective in ameliorating both 
somatic and autonomic neuropathy in diabetes. 
Gamma Linolenic acid 
Linoleic acid, an essential fatty acid is metabolized to gamma linolenic 
acid, which serves as an important constituent of neuronal membrane 
phospholipids, and also serves as a substrate for prostaglandin E formation 
which is vital for preserving nerve blood flow. 
Aminoguanidine 
      It is an inhibitor of AGE and inspite of its serious toxic profile, successive 
generations of aminoguanidine are under trial and holds promise for the 
future. 
Neurotrophic Therapy 
 Nerve growth factor binds to high and low affinity nerve growth factor 
receptors present on small, unmyelinated fibers of the sensory neurons of the 
peripheral nervous system, on sympathetic neurons in the autonomic nervous 
system, and in regions of the central nervous system. This therapy is under 
trial and is directed towards regeneration of damaged nerves. 
MANAGEMENT AIMED AT SYMPTOMS 
           Postural hypotension in the patient with DAN can present  difficult 
management problem. Elevating the blood pressure in the standing position 
must be balanced against preventing hypertension in the supine position 
Supportive garment 
Attempts should be made to increase venous return from the periphery 
using total body stockings. The patient should be instructed to put them on in 
the lying down position and not to remove them until returning to the supine 
position. In severe cases an air force anti-gravity suit may be needed. 
 Drug therapy           
Some patients may benefit from treatment with 9-fludrocortisone 0.5 
mg daily and supplementary salt 2 to 6 g daily. Metoclopramide 10 mg three 
times daily may be helpful in patients with dopamine excess or increased 
sensitivity to dopaminergic stimulation. Patients with alpha 2 adrenergic 
receptor excess may respond to yohimbine, 10 mg three times a day. Other 
drugs that are helpful include clonidine, midodrine, dihydroergotamine, 
caffeine and octreotide. 
Nutritional Supplements 
Antioxidants 
          Antioxidants play a pivotal role in preventing progression of diabetic 
neuropathy.Their role in autonomic neuropathy is validated through many 
trials., eg. Ziegler et al proved the efficacy of anti oxidant in CAN. The 
following agents are recommended. 
• Vitamin A 
• Vitamin C 
• Vitamin E 
• Selenium 
• N Acetyl Cysteine 
• Gingko Biloba Extract 
Others 
             Chromium, Biotin, Niacin, Inositol, Taurine, Magnesium have also 
been tried and is recommended for prevention of DAN. 
ECG CHANGES IN DIABETES 
 The length of the QT interval is influenced by autonomic nervous tone. 
A long QT interval may reflect an imbalance between right and left heart 
sympathetic nerve activity.  
          Autonomic instability reflected by abnormally long QT intervals 
increases the risk of severe abnormal rhythms and sudden death. In the EURO 
Diabetes IDDM complications study, 16% had prolonged corrected QT 
interval. Studies have shown that QTc prolongation is associated with major 
degrees of autonomic neuropathy63. 
 A meta analysis concluded that QTc prolongation is a specific 
indication of autonomic failure64. 
 Increase of QT dispersion is a major determinant of risk of mortality in 
type 2 diabetes. QT dispersion is the difference between longest and shortest 
QT intervals recorded by 12 lead ECG. 
 Increasing QT dispersion reflects electrical instability of left 
ventricular musculature65. 
 Diabetics have prolonged PR interval and more leftward frontal QRS 
axis than their non diabetic counterparts66. 
  There is an increased incidence of intraventricular conduction blocks in 
diabetic patients that that of the normal67.  
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 MATERIALS AND METHODS  
MATERIALS  
1. Study Population  
 Fifty diabetic patients attending Diabetology Outpatient Department, 
Govt. Royapettah Hospital, Chennai. These subjects were selected after 
scrutinizing them for exclusion criteria. 
2. Control Populations  
 Fifty patients attending General Medical Outpatient Department at 
Govt. Royapettah Hospital. These subjects were age and sex matched 
controls. 
3. Place of Study  
 Out patient department  
 Diabetology department  
 Govt. Royapettah Hospital 
 Kilpauk Medical College.  
           Chennai. 
4. Period of Study   
 February  2005 – July 2005.  
 METHODS  
 All study group patients and controls were subjected for thorough 
physical examination. Blood samples were drawn and subjected to estimation 
of plasma glucose and renal function tests.  
Exclusion Criteria  
• Age >65 years 
• Documented coronary artery disease 
• Documented valvular or congenital heart disease 
• Hypertension 
• Chronic obstructive pulmonary disease 
• History of drug intake – Beta Blocker, digoxin, calcium channel 
blockers.  
• Hypothyroidism  
• Chronic kidney disease and uremia  
• Treatment for parkinsonism  
Autonomic dysfunction was assessed using following parameters 
Parasympathetic functions 
• Tachycardia in resting ECG 
• Heart rate response to deep breathing  
Sympathetic Functions   
 • Blood pressure response to standing  
• QTc prolongation   
Electrocardiogram 
 Resting ECG taken in both study group and control group using a three 
leaded Schillar Cardiovit AT machine. ECG during deep breathing was 
recorded only in study  group (Diabetics) using single leaded BPL ECG 
machine. 
 The patients were made to lie down quietly. Then they were asked to 
take deep breath in and out at a rate of 6 breaths / minute. (5 seconds for 
inspiration and 5 seconds for expiration) which produces a maximum heart 
rate variation. A continuous ECG was recorded for minute.  
 E: I ratio was measured and the mean of the longest of the R-R interval 
during expiration to the mean of shortest R-R interval during inspiration was 
calculated. The E:I ratio was ≤1.10 in diabetic autonomic dysfunction. 
 QTc interval    
 R-R and QT intervals were measured in the resting ECG tracing. The 
lead considered here is V2 chest lead. 
 The QT interval was measured from the beginning of QRS complex to 
the end of downslope of the T wave (crossing the  
iso-electric line). When a U wave was present, the QT interval was measured 
to the nadir of T and U wave. The corrected QT interval for the given cardiac 
cycle length (QTc) was calculated using BAZETT 's formula. 
  QTc =     QT 
    √R-R interval (sec) 
A QTc interval of more than 460 msec is considered abnormally 
prolonged.  
STATISTICAL ANALYSIS 
 Statistical significance of the data obtained in the study were done 
using Students T test. In places where the data did not follow Normal 
distribution, Mann Whitney test was employed. For the other datas unpaired t 
test was used to arrive at probability values and to test Null hypothesis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Observations & 
Results 
 OBSERVATIONS AND RESULTS 
TABLE - 1 
AGE DISTRIBUTION 
Study Group Control Group 
Age (Years) 
No. % No. % 
20 – 30 1 2 2 4 
31 – 40 9 18 2 4 
41 – 50 19 38 21 42 
51- 60 21 42 25 50 
Inference 
Most of patients in the study population belong to the age group of 40 
to 60 years.  
TABLE - 2 
AGE  
Age 
 
Group 
Range (Years) Mean (Years)±SD 
Study  36 – 58 48.52 ± 6.9377 
Control  29 – 61 49.94 ± 7.5279 
P = 0.3292  
Inference  
There is no statistically significant difference in the  mean age of both 
study and control population proving that there is no age bias. 
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 TABLE – 3 
AGE AT DIAGNOSIS 
STUDY GROUP 
Years Number Percentage (%) 
21- 30 4 8 
31 – 40 16 32 
41 – 50 23 46 
51 – 60 7 14 
Inference 
46% of the study group had their diabetes diagnosed at age between 41 
and 50 years. 
TABLE - 4 
GENDER DISTRIBUTION 
Male Female 
Group 
No. % No. % 
Study 19 38 31 62 
Control 31 62 19 38 
Inference 
62% of the study population were females suggesting the higher 
prevalence of diabetes in them. 
TALBE - 5 
 PERCENTAGE OF SMOKERS 
Smokers Non Smokers 
Group 
No. % No. % 
Study 15 30 35 70 
Control 16 32 34 68 
Inference 
Among the study population 30% were smokers. There is no 
significant difference in risk factor of smoking between study and control 
group. 
TABLE - 6 
PERCENTAGE OF ALCOHOLICS 
Consumes Alcohol No Consumption 
Group 
No. % No. % 
Study 12 24 38 76 
Control  9 18 41 82 
Inference 
 
24% of the study population consumed alcohol. 
16% of the study population were both smokers and alcoholics.  
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 TABLE - 7 
DURATION OF DIABETES MELLITUS 
Study Group  Duration   
(years) No. % 
0 – 5 27 54 
6-10 17 34 
11 – 15 3 6 
16 – 20 3 6 
Mean ± SD (years): 6.228 ± 4. 815112 
Inference 
Nearly 54% of the patients in the study group have had diabetes for 
less than 5 years.  
TABLE – 8 
SIGNIFICANT POSTURAL DROP OF SYSTOLIC BLOOD 
PRESSURE 
Postural  fall of SBP 
(>30mm Hg) Number Percentage (%) 
Study 5 10% 
Control - - 
 
Inference 
 10% of the diabetic study group had significant postural drop of 
systolic blood pressure on standing suggesting sympathetic nervous system 
dysfunction.  
 DURATION OF DIABETES MELLITUS
0 – 5 years
54%6 - 10 years
34%
11 – 15 years
6%
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6%
 TABLE - 9 
RESTING HEART RATE 
Group Range (bpm) Mean (bpm)±SD 
Study  56-100 86.16±7.6 
Control  60-100 76.64±9.18 
P = 0.0000   
Inference 
The resting heart rate of study population (86.16±7.6) is significantly 
higher than that of the control population  
(76.64±9.18). 
 
TABLE – 10 
R–R INTERVAL 
Group Range (m sec) Mean (m sec)±SD 
Study 600 – 1080 701.6 ± 72.96519 
Control 600 – 1000 794 ± 92.25077 
P = 0.0000  
Inference 
The R – R interval of study group (701.6) is significantly lower than 
that of control group (794). 
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 TABLE – 11 
PR INTERVAL  
Group Range Mean(msec)±SD 
Study  120 - 300 163 ± 32.84 
Control  120 - 180 136 ± 19. 79487 
P = 0.00003   
Inference 
 PR interval of study population (163) is significant higher than that of 
control (136) group (P<0.05). 
TABLE - 12 
QRS DURATION 
Group Range (m sec) Mean (m sec) 
± SD 
Study 40 – 120 57.2 ± 17.61725 
Control  40 - 100 53.6 ± 16. 87408 
P = 0.2 99285     
Inference 
 There is no statistically significant (P>0.05) difference in QRS 
duration of study and control groups.  
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 TABLE - 13 
QRS AXIS 
Group Range (degree) Mean (degree) ± SD 
Study  - 30 to +90 31.6 ± 34.36657 
Control  0 to 100 54 ± 35. 74285 
P = 0.001885   
Inference 
 The QRS axis of study group is more towards leftward (31.6°) 
compared to control group (54°) which is statistically significant (P<0.05). 
TABLE - 14 
ECG CHANGES OF ISCHEMIA AND INFARCTION 
Evidence of Ischemia Evidence of infarction 
Group 
No. % No. % 
Study  14 28 5 10 
Control  5 10 2 4 
Inference 
 28% had evidence of ischemia in the study population and 10% had 
evidence of infarction suggesting that silent infarction had occurred. 
 0
5
10
15
20
25
30
35
40
P
e
r
c
e
n
t
a
g
e
Evidence of Ischemia Evidence of infarction
ECG CHANGES OF ISCHEMIA AND INFARCTION
Study Control
 TABLE - 15 
CORRELATION BETWEEN ECG AND SYMPTOMS OF IHD 
Symptomatic Asymptomatic 
Group ECG changes 
No. % No. % 
Study 19 12 63.15 7 36.84 
Control 7 6 85.71 1 14.28 
Inference 
 Study group population has more number of patients with 
asymptomatic heart disease (36.8%) when compared to the control group 
(14.28%). 
 
TABLE - 16 
INCIDENCE OF INTRAVENTRICULAR CONDUCTION DEFECTS 
Group IVCD Percent 
Study 3 6% 
Control - - 
 
Inference 
 IVCD is present in 6% of the study populations. 
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 TABLE - 17 
QTc INTERVAL 
QTc Interval 
Group 
Range (msec) Mean (msec) ± SD 
Study 353 - 487 400.62 ± 32.18942 
Control 319 - 410 361.10 ± 22.3828 
P = 0.0000     
Inference 
QTc of the diabetic population (400.6msec) was significantly (P 
=0.0000) prolonged when compared to that of the control 
population(361msec). 
TABLE - 18 
E: I RATIO 
E:I Ratio Number Percent (%) 
Normal  > 1.1 35 70 
Abnormal ≤ 1.1 15 30 
 
Inference 
 30% of study group population have abnormal E:I ratio suggesting 
early parasympathetic dysfunction. 
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Discussion  
 
 DISCUSSION 
 The diabetic population had a mean resting heart rate that was (86.16 
bpm) higher than that of the control population  
(76.64 bpm). This difference was statistically significant implying higher 
resting heart rate  in diabetic population. This is probably due to cardiac 
autonomic dysfunction, more specifically parasympathetic damage. Ewing et 
al. found that the parasympathetic nerves are the earliest to be involved 
followed by sympathetic nerves in autonomic neuropathy.  
 The clinical utility of the knowledge that the resting heart rate is often 
higher in diabetics due to parasympathetic damage is that such patients need 
to be studied in great detail for cardiac autonomic neuropathy, since they are 
prone to develop sudden and unexpected cardiac arrest more so during 
procedures like  anaesthesia. Mangoni AA, Mircoti L. showed that resting 
tachycardia decreases the distensibility of the vascular wall, and increases the 
risk of atherosclerosis, all favouring coronary artery disease.  
 That the resting heart rate is higher in diabetics when compared to non 
diabetics is reaffirmed by the fact that R-R interval is lower in study group 
(701.6msec) than that of the non diabetic group (794msec). 
 Freeman R, Saul P et al. in their spectral analysis of heart rate in DAN; 
Arch, Neurol; 1991 established that R-R interval analysis served  as a means 
for early assessment of CAN. 
  The PR interval was significantly prolonged in diabetics suggesting a 
delayed conduction across atrioventricular node paving way for conduction 
abnormalities. This evidence of first degree heart block could be the cause for 
syncope. It has been established in studies that some cases of PR prolongation 
associated with CAN can predispose to atrial fibrillation. 
 The leftward axis (31.6°) is also indicative of bundle branch blocks. 
There is an increased incidence of intraventricular conduction blocks in 
diabetics (6%). 
 Conduction blocks at various levels and in varying degrees makes 
patients with CAN prone to symptoms of heart block and sudden cardiac 
death as was shown by Erickson et al. in his Primary Prevention study which 
asserted the fourfold risk of higher atrio ventricular block in patients with 
RBBB. 
 A prolonged corrected QT interval, as evidenced in this study, where 
the QTc in study population is 400.62 msec  as against 361.10 msec of the 
control population, indicates an imbalance between right and left sympathetic 
innervations. JM Cronin, MM Kadrifrek, EJ Bastyr University of Michigan; 
Diabetes Care; Vol.13, showed that as a group, diabetic patients with greater 
than or equal to 2 abnormalities of cardiac autonomic function had a longer 
QTc interval than those with no evidence of cardiac autonomic neuropathy.  
 Diabetic patients with a regional sympathetic imbalance and QTc 
interval prolongation may be at greater risk for arrhythmias predisposing them 
to sudden cardiac death.  Eric A. Witset, Pentittii M. Rautaharju, Sheila A. 
Veinmami. Diabetes Care; 28:20415 – 20417 in a population based study 
examined the risk of primary cardiac arrest associated with QTc prolongation 
and concluded that diabetic patients in the upper quartile of QT index 
distribution had a three fold risk of primary cardiac arrest.  
Kahn et al. demonstrated that prolongation of the QTc interval 
increased the risk of intractable ventricular arrhythmias and sudden death.  
Diabetic study population showed (38%) significant ECG changes of 
ischemia and infarction proving that diabetic patients have a higher rate of 
coronary artery disease; significantly these patients remain asymptomatic 
(36.84%) owing to autonomic neuropathy. This is in concurrence with the 
results of Valensi P, Sashs R N et al who conducted a study on predictive 
value of CAN in diabetic patients with or without silent myocardial ischemia.  
Silent ischemia is significantly more frequent in diabetic patients with 
than in those without autonomic neuropathy. A reduced appreciation of 
ischemic pain can impair early recognition of myocardial ischemia or 
infarction and delay appropriate therapy making it necessary to screen 
diabetic patients for ischemia and CAN frequently.  
 Heart rate variability to deep breathing was abnormal in 30% of study 
subjects. Decreased HRV is considered the earliest indication of CAN and is 
often the most frequent finding in symptomatic CAN. The demonstration of 
loss of HRV during deep breathing indicates the presence of vagal 
denervation of the heart and is also associated with increased rate of 
progression of coronary atherosclerosis. Decreased vagal activity limits 
exercise tolerance making these individuals prone to syncope and predisposed 
to sudden cardiac death. 
10% of the diabetic study group showed orthostatic  hypotension, 
which is usually due to damage to efferent sympathetic vasomotor fibers, 
particularly in splanchnic vasculature. Diminished cardiac acceleration and 
cardiac output, particularly in association with exercise may also be important 
in the presentation of this disorder. Some of these patients presented with 
light headedness and presyncopal symptoms, while some were asymptomatic. 
Apart from the pain of peripheral neuropathy, symptoms of orthostatic 
hypotension is the most troublesome to treat in diabetic patients. 
CAN can occur as early as one year after diagnosis of type 2 DM. In 
this study 54% of population had diabetes for 5 years and the age at diagnosis 
was between 40-50 years of age for most indicating late diagnosis and hence 
higher prevalence of CAN. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 CONCLUSION 
 The following ECG parameters were abnormal in Diabetic study group 
as compared to control population. 
 The resting heart rate (86.16±7.6) was significantly (P<0.05) higher 
than that of non diabetic controls (76.64±9.18). 
 The RR interval was narrow in diabetic (701.6 ± 72.9 msec) as 
compared to control subjects (794 ± 92.25 msec) which was 
statistically significant.  
 The PR interval in diabetics (163 ± 32.84 msec) was prolonged as 
compared to control (136 ± 19.794) and was statistically significant 
(P= 0.0003).  
 There was a leftward deviation of QRS axis among diabetics (31.6°) as 
compared to controls (54°). 
 QTc interval was prolonged (400.62 ± 32.18 msec) in diabetic study 
population which was significant (P=0.0000). 
 There was an increased prevalence of ischemia and infarction in 
diabetics as was evidenced by ECG changes (38%).  
 Asymptomatic ischemic heart disease was more common (36.84%) 
among diabetics as compared to control subjects.  
 Varying degrees of conduction blocks were prevalent in diabetics 
(6%). 
 Cardiac dysautonomia was demonstrated in the study population using 
the following parameters. 
 Abnormal E:I ratio (≤ 1.1) (30%). 
 Prolonged QTc interval (> 460 msec) (6%) 
 Postural fall in systolic blood pressure (> 30 mmHg) (10%). 
This study shows the high prevalence of cardiac dysautonomia in type 
2 diabetics. Most of these patients remain asymptomatic. Some of the patients 
with CAN had diabetes for only as few as 5 years proving the DCCT result 
that the disease process begins early and it may remain asymptomatic until 
later stages.  
It can be recommended that a baseline determination of cardiac 
autonomic function be performed upon diagnosis in type 2 diabetes followed 
by a yearly repeat test.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Proforma  
 PROFORMA 
Name 
OP No. 
Age  
Sex 
Age of onset of DM 
Duration of DM 
Treatment History 
Dietary Habits 
History of Angina 
History of Postural hypotension:  (Faintness / Dizziness) 
History of Smoking  
History of Alcohol consumption 
Body Mass Index 
Pulse (bpm)  
Blood pressure (mm Hg) 
 Supine : 
 Standing  : 
System Examination  
Cardio Vascular System  
Respiratory System 
 INVESTIGATIONS 
a) Blood Sugar  Fasting  
Post prandial  
b) Blood Urea  
c) Serum creatinine 
d) Hemoglobin A1 C 
e) Hemoglobin 
f) S. Cholesterol 
 
ELECTROCARDIOGRAM 
a) Heart rate 
b) R-R interval 
c) PR interval 
d) QRS axis 
e) QRS duration 
f) QTc Interval  
g) E:I ratio 
h) ST-T changes 
i) Conduction abnormalities  
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 ABBREVIATIONS 
ADA  - American Diabetes Association  
AGE  - Advanced Glycosylation End products 
ANS  - Autonomic Nervous System  
BMI  - Body Mass Index 
BP STN - Blood Pressure Standing  
BP SUP - Blood Pressure Supine  
BP  - Blood Pressure 
CAD  - Coronary Artery Disease  
CAN  - Cardiac Autonomic Neuropathy 
CNS  - Central Nervous System 
D  - Diagnosis 
DAN  - Diabetic Autonomic Neuropathy 
DCCT - Diabetes Control and Complications Trial  
DM  - Diabetes Mellitus  
DUR DM - Duration of Diabetes Mellitus  
DUR  - Duration  
ECG  - Electro cardiogram  
FPG  - Fasting Plasma Glucose  
H/O A - History of Alcohol Intake 
H/O ANG - History of Angina 
H/O PH - History of Postural Hypotension 
H/O S  -        History of Smoking 
 HR  - Heart Rate 
HRV  - Heart Rate Variability  
IDDM - Insulin Dependent Diabetes Mellitus  
IFG  - Impaired Fasting Glucose 
IGF  - Insulin like Growth Factor  
IGT  - Impaired Glucose Tolerance  
IVCD  - Intra Ventricular Conduction Defects 
LBBB  - Left Bundle Branch Block  
NGF  - Nerve Growth Factor 
NIDDM - Non Insulin Dependent Diabetes Mellitus 
OGTT - Oral Glucose Tolerance Test 
P  - Pulse 
PNS  - Peripheral Nervous System 
PPG  - Post Prandial Glucose 
RBBB - Right Bundle Branch Block 
SCD  - Sudden Cardiac Death 
VEGF - Vascular Endothelial Growth Factor  
WHO  - World Health Organisation 
ROS  - Reactive Oxygen Species   
PKC  - Protein Kinase C 
NOS  - Nitric Oxide Synthetase  
 STUDY GROUP 
                     
   
  ECG ST/T 
S.No. Age Sex BMI H/o 
 S. 
H/o 
A. 
Dur 
of 
DM 
Age 
at  D 
H/o 
ANG 
H/o 
PH 
 
Pulse  BP SUP BP STN HR RR  PR QRS Axis 
QRS 
DUR QTC E : I IVCD ST T Q 
1 40 M 23 - + 3 37 - - 110 140/80 142/86 88 680 160 30 40 390 1.2 - - - - 
2 57 M 23.5 + + 13 44 + + 90 130/70 120/70 85 700 160 50 40 382 0.9 - + + - 
3 55 M 22 + - 10 45 + - 86 132/80 126/72 83 720 140 60 40 380 1.7 - - - - 
4 55 M 22 - - 7 48 - + 110 120/70 80/70 81 740 120 -30 60 395 1.3 - - - - 
5 53 F 21 - - 5 48 - - 90 120/70 100/70 85 700 160 0 40 440 0.62 - + - - 
6 47 F 20 - - 7 40 - - 100 100/70 90/70 100 600 180 0 60 415 1.0 - - - + 
7 40 F 21 - - 8 32 + + 90 92/70 90/70 81 740 200 30 40 373 1.6 - + - - 
8 38 F 21 - - 1 37 - - 114 110/70 100/70 83 720 160 30 40 353 1.2 - - - - 
9 40 M 23 + - 5 35 + - 118 144/90 112/72 81 740 120 60 60 418 1.1 - - - - 
10 57 F 22 - - 5 52 - - 110 134/72 112/74 75 800 120 30 60 382 1.26 - - - - 
11 50 F 21 - - 10 40 + - 86 134/80 120/72 73 820 160 60 80 376 1.46 + - - - 
12 48 F 20 - - 20 28 - - 80 124/72 110/70 94 640 120 50 40 400 0.8 - - + - 
13 40 F 21 - + 8 32 + - 88 140/90 142/90 100 600 160 40 60 390 1.5 - - - - 
14 50 F 22 - - 9 41 - - 84 100/80 90/70 88 680 120 80 40 440 0.82 - - - - 
15 55 F 21.5 - + 8 47 - - 94 110/70 100/70 85 700 140 0 60 361 1.76 - - - - 
16 53 F 22 - + 10 43 - - 92 110/70 90/70 94 640 200 30 80 425 0.8 - - - - 
17 50 M 23 + - 3 47 + - 106 110/70 114/72 83 720 180 30 60 380 1.3 - - - + 
18 50 M 23.5 + + 1 49 - - 105 130/80 120/70 94 640 160 0 40 375 1.32 - - - - 
19 42 F 21 - - 5 37 - - 90 140/70 130/72 85 700 160 90 50 382 1.46 - - - - 
20 45 F 21 - - 2 43 + - 84 124/94 100/90 85 700 140 60 60 361 1.26 - - - - 
21 54 M 23 + + 6 48 - - 94 124/72 120/70 80 750 160 -30 80 375 1.6 - - - - 
22 36 M 24 + + 6 30 + - 90 100/74 110/74 94 640 200 40 60 450 0.6 - - - - 
23 47 F 22.5 - - 7 40 + - 86 110/70 120/70 88 680 120 60 40 439 0.7 - + - - 
24 52 F 22 - - 6 46 + - 88 100/64 90/60 90 670 140 60 40 420 1.3 - + - - 
25 54 M 23 + - 20 34 - - 110 132/40 120/64 95 630 160 40 60 405 1.3 - - - + 
26 54 F 22 - - 2 52 + - 104 142/70 110/60 94 640 130 0 80 425 0.5 - + + - 
27 55 F 22 - - 5 50 - - 85 140/84 140/60 100 600 120 -30 40 390 1.62 - - - - 
28 35 F 21 - - 1 34 - - 88 138/72 140/90 87 720 200 0 60 353 1.4 - - - - 
 STUDY GROUP 
                     
   
  ECG ST/T 
S.No. Age Sex BMI H/o 
 S. 
H/o 
A. 
Dur 
of 
DM 
Age 
at  D 
H/o 
ANG 
H/o 
PH 
 
Pulse  BP SUP BP STN HR RR  PR QRS Axis 
QRS 
DUR QTC E : I IVCD ST T Q 
29 50 F 21.5 - - 2 48 - - 98 130/80 138/72 95 630 160 -40 80 380 1.6 - - - - 
30 54 M 24 + - 2 52 - - 100 110/70 110/70 100 600 180 60 60 415 1.6 - - - - 
31 55 M 23 + + 3 52 - - 91 134/70 110/70 83 720 160 30 40 428 1.36 - - - - 
32 50 F 22.5 - - 3 47 + - 85 130/72 120/64 88 680 140 40 120 403 1.36 + + + - 
33 58 M 23 - - 18 40 - - 89 124/68 110/70 88 680 160 40 40 439 0.6 - - - - 
34 45 F 22 - - 2 43 + - 99 110/70 90/62 87 690 180 30 60 386 1.4 - - + - 
35 53 M 23.5 - - 2 51 - - 106 132/70 100/62 85 700 180 40 40 382 1.36 - - - + 
36 45 M 23 + + 6 39 + - 110 110/70 100/70 87 690 160 70 60 362 0.92 - + - - 
37 40 F 22 - - 4 36 - - 84 134/70 120/70 85 700 160 60 80 361 1.42 - - - - 
38 48 F 21 - - 3 45 + - 74 130/80 126/70 88 680 160 40 60 487 0.7 - + - - 
39 59 F 21 - - 5 54 - - 94 124/68 120/60 83 720 140 30 60 380 1.2 - - - - 
40 43 F 23 - - 2 41 - - 75 110/72 90/70 85 700 200 0 40 361 1.6 - - - - 
41 30 F 21 - - 4 26 - - 98 110/74 100/78 81 740 160 0 40 372 1.32 - - - - 
42 43 F 22 - - 5 38 - - 94 132/80 124/60 79 760 200 30 80 413 1.3 - - + - 
43 56 F 22.5 - - 1 55 - - 89 130/80 110/74 88 680 300 90 80 463 0.9 - - - - 
44 54 F 22 - - 10 44 - - 106 110/74 100/90 81 740 140 30 80 395 1.42 + - + - 
45 40 M 22 + - 15 25 + - 109 134/82 110/74 81 740 160 30 60 395 1.46 - + - - 
46 50 M 23 + + 10 40 + - 110 132/78 124/70 88 680 160 90 40 440 1.62 - - - + 
47 58 M 23 + - 15 43 - + 89 140/74 100/68 85 700 160 60 60 382 1.5 - - - - 
48 54 F 23.5 - - 6 48 - - 88 124/70 110/64 83 720 240 0 40 476 0.9 - - - - 
49 48 M 22 + + 1 47 - - 96 134/72 124/70 81 740 180 90 40 418 1.7 - - - - 
50 47 F 21 - - 5 42 - - 64 118/72 102/64 56 1080 180 30 60 418 1.2 - - - - 
 
 
 CONTROL GROUP 
                    
  ECG ST/T S. 
No. Age Sex 
H/o 
S. 
H/o 
A. 
H/o 
ANG 
H/o 
PH  Pulse  
BP 
SUP 
BP 
STN HR RR  PR QRS Axis 
QRS 
DUR QTC IVCD ST T Q 
1 52 F - - - - 88 124/70 120/72 88 680 120 60 40 365 - - - - 
2 53 F - - + - 80 132/80 130/84 83 720 100 60 40 357 - + - - 
3 54 M - + + - 72 130/80 128/74 71 840 120 60 40 340 - - - - 
4 45 M + + - - 74 130/72 130/70 75 800 140 30 60 382 - - - - 
5 55 M + - - - 60 124/68 120/64 68 880 120 90 60 344 - - - - 
6 46 M - - + - 60 130/70 120/70 63 960 160 40 40 330 - - - - 
7 42 M - + - - 82 120/78 120/70 79 760 120 90 40 368 - - - - 
8 56 M - + - - 81 100/70 110/70 83 720 120 60 60 357 - - - - 
9 44 M - - - - 74 110/78 110/70 75 800 120 60 40 360 - - - - 
10 58 F - - - - 66 120/82 120/70 71 840 140 60 40 362 - - - - 
11 55 F - - - - 72 138/74 130/70 94 640 120 60 60 408 - - - - 
12 50 F - - - - 60 130/70 134/70 68 880 140 30 80 344 - - - - 
13 46 F - - - - 72 130/70 130/70 70 860 160 50 40 345 - - - - 
14 50 M + - - - 84 110/70 110/70 88 680 120 80 40 341 - - - - 
15 60 M - - - - 66 110/80 100/70 68 880 160 0 40 387 - - - - 
16 47 M - - - + 70 140/70 150/80 79 760 160 90 80 344 - - - - 
17 48 F - - - - 70 110/76 110/70 88 680 180 60 100 340 - - - - 
18 60 F - - + - 90 110/70 100/70 100 600 160 90 40 375 - - - + 
19 54 M + - - - 80 130/70 128/70 81 740 120 30 40 372 - - - - 
20 48 M - - - - 60 140/80 130/70 60 1000 120 90 60 320 - - - - 
21 53 M - + - - 86 130/70 128/70 73 820 120 30 40 360 - - - - 
22 46 M - - - - 84 120/70 110/70 79 760 140 40 60 344 - - - - 
23 48 M + - + + 90 128/72 120/70 75 800 160 60 60 360 - - - + 
24 51 F - - + - 76 134/74 130/70 71 840 120 80 40 340 - - + - 
25 60 F - - - - 58 128/70 132/74 68 880 120 90 80 340 - - - - 
26 55 F - - - - 74 120/70 110/74 60 1000 160 90 40 320 - - - - 
27 51 F - - - - 92 130/70 128/80 75 800 160 60 80 360 - - - - 
28 60 F - - + - 88 124/70 120/70 88 680 120 60 40 365 - - - - 
29 48 M + - - + 90 132/70 130/74 70 860 120 60 80 410 - - - - 
30 54 F - - - - 68 130/74 132/74 75 800 140 30 60 382 - - - - 
 CONTROL GROUP 
                    
  ECG ST/T S. 
No. Age Sex 
H/o 
S. 
H/o 
A. 
H/o 
ANG 
H/o 
PH  Pulse  
BP 
SUP 
BP 
STN HR RR  PR QRS Axis 
QRS 
DUR QTC IVCD ST T Q 
31 58 M - - - - 70 128/70 132/70 68 880 160 60 60 366 - - - - 
32 43 M + - + - 72 126/70 120/70 75 800 120 50 80 382 - + - - 
33 29 M + + - - 88 130/84 120/80 88 680 120 90 40 341 - - - - 
34 45 F - - - - 70 130/80 120/70 71 840 140 0 40 362 - - - - 
35 48 M - - - - 90 134/70 130/72 79 760 120 90 60 344 - - - - 
36 57 M + - + - 84 128/80 120/74 88 680 120 90 40 365 - + - - 
37 55 F - - - - 72 132/70 130/72 68 880 160 80 60 344 - - - - 
38 51 M + - - + 70 128/70 120/70 70 860 120 30 40 388 - - - - 
39 46 F - - - - 64 124/72 120/70 68 880 140 60 40 387 - - - - 
40 50 M + + + - 70 110/70 110/70 79 760 160 90 40 368 - - - - 
41 23 M - + + - 90 110/10 114/70 85 700 120 30 80 390 - - - - 
42 55 M + - - - 80 120/70 110/70 68 880 140 50 80 366 - - - - 
43 60 M - - - + 80 134/72 130/70 83 720 160 60 60 404 - - - - 
44 46 M + + - - 82 128/74 120/70 79 760 180 30 40 368 - + - - 
45 58 M + - - - 70 132/70 130/80 75 800 120 0 40 382 - - - - 
46 40 F - - - - 72 128/80 120/80 71 840 120 90 40 340 - - - - 
47 37 M - - - - 84 132/80 130/70 91 660 160 90 40 369 - - - - 
48 47 M + - - - 89 132/70 130/74 94 640 120 80 60 400 - - - - 
49 53 F - - - - 70 134/70 130/72 67 900 120 60 80 319 - - - - 
50 46 M + - - - 70 128/70 124/74 79 760 140 30 40 344 - - - - 
 
